drugset / Trial / NCT01214096
Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
Timeline
- Start
- 2010-07
- Primary completion
- 2011-01
- Completion
- 2011-01
Outcome
Outcome not reported
Stopped: “The same protocol has been launched in United States.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HUMAN NEUREGULIN-1 RECOMBINANT (177-237) | Protein / enzyme biologic | 0.6 ug/kg | Subcutaneous |
| Subject | HUMAN NEUREGULIN-1 RECOMBINANT (177-237) | Protein / enzyme biologic | 1.2 ug/kg | Subcutaneous |